Does the media prefer CRMD or MLYS?

In the previous week, Mineralys Therapeutics had 2 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Mineralys Therapeutics and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Mineralys Therapeutics' score of 0.93 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Mineralys Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HRMY or CRMD?

In the previous week, Harmony Biosciences had 22 more articles in the media than CorMedix. MarketBeat recorded 24 mentions for Harmony Biosciences and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Harmony Biosciences' score of 0.94 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 9 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor RAPP or CRMD?

In the previous week, Rapport Therapeutics had 16 more articles in the media than CorMedix. MarketBeat recorded 18 mentions for Rapport Therapeutics and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Rapport Therapeutics' score of -0.14 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation and earnings, HCM or CRMD?

HUTCHMED has higher revenue and earnings than CorMedix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $549.12M 3.97 $456.91M N/A N/A CorMedix $311.71M 1.87 $163.05M $2.13 3.49

Is HCM or CRMD more profitable?

CorMedix has a net margin of 45.25% compared to HUTCHMED's net margin of 0.00%. CorMedix's return on equity of 45.57% beat HUTCHMED's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A CorMedix 45.25% 45.57% 24.76%

Does the media favor HCM or CRMD?

In the previous week, HUTCHMED had 1 more articles in the media than CorMedix. MarketBeat recorded 3 mentions for HUTCHMED and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat HUTCHMED's score of 1.05 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation & earnings, CRMD or GHRS?

CorMedix has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $311.71M 1.87 $163.05M $2.13 3.49 GH Research N/A N/A -$48.26M -$0.92 N/A

Does the media refer more to CRMD or GHRS?

In the previous week, GH Research had 9 more articles in the media than CorMedix. MarketBeat recorded 11 mentions for GH Research and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat GH Research's score of 0.70 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive GH Research 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CorMedix (CRMD) Competitors

$7.44 -0.07 (-0.93%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$7.45 +0.01 (+0.13%)

As of 08/7/2026 07:37 PM Eastern

Compare

CRMD vs. MLYS, HRMY, RAPP, HCM, and GHRS

Should you buy CorMedix stock or one of its competitors? MarketBeat compares CorMedix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CorMedix include Mineralys Therapeutics (MLYS), Harmony Biosciences (HRMY), Rapport Therapeutics (RAPP), HUTCHMED (HCM), and GH Research (GHRS). These companies are all part of the "pharmaceuticals" industry.

How does CorMedix compare to Mineralys Therapeutics?

CorMedix (NASDAQ:CRMD) and Mineralys Therapeutics (NASDAQ:MLYS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

CorMedix has a net margin of 45.25% compared to Mineralys Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

CorMedix presently has a consensus target price of $14.86, suggesting a potential upside of 99.69%. Mineralys Therapeutics has a consensus target price of $49.33, suggesting a potential upside of 80.38%. Given CorMedix's stronger consensus rating and higher probable upside, equities analysts clearly believe CorMedix is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

CorMedix has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.87	$163.05M	$2.13	3.49
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

34.2% of CorMedix shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CorMedix has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

In the previous week, Mineralys Therapeutics had 2 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Mineralys Therapeutics and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Mineralys Therapeutics' score of 0.93 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Mineralys Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CorMedix beats Mineralys Therapeutics on 11 of the 14 factors compared between the two stocks.

How does CorMedix compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and CorMedix (NASDAQ:CRMD) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Harmony Biosciences currently has a consensus target price of $45.50, suggesting a potential upside of 18.46%. CorMedix has a consensus target price of $14.86, suggesting a potential upside of 99.69%. Given CorMedix's stronger consensus rating and higher possible upside, analysts plainly believe CorMedix is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Harmony Biosciences had 22 more articles in the media than CorMedix. MarketBeat recorded 24 mentions for Harmony Biosciences and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Harmony Biosciences' score of 0.94 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	9 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Harmony Biosciences has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

CorMedix has a net margin of 45.25% compared to Harmony Biosciences' net margin of 18.88%. CorMedix's return on equity of 45.57% beat Harmony Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
CorMedix	45.25%	45.57%	24.76%

CorMedix has lower revenue, but higher earnings than Harmony Biosciences. CorMedix is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.58	$158.69M	$3.08	12.47
CorMedix	$311.71M	1.87	$163.05M	$2.13	3.49

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 3.5% of CorMedix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CorMedix beats Harmony Biosciences on 9 of the 17 factors compared between the two stocks.

How does CorMedix compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and CorMedix (NASDAQ:CRMD) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

CorMedix has a net margin of 45.25% compared to Rapport Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
CorMedix	45.25%	45.57%	24.76%

Rapport Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

CorMedix has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
CorMedix	$311.71M	1.87	$163.05M	$2.13	3.49

Rapport Therapeutics currently has a consensus target price of $57.86, suggesting a potential upside of 27.19%. CorMedix has a consensus target price of $14.86, suggesting a potential upside of 99.69%. Given CorMedix's higher probable upside, analysts plainly believe CorMedix is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

34.2% of CorMedix shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Rapport Therapeutics had 16 more articles in the media than CorMedix. MarketBeat recorded 18 mentions for Rapport Therapeutics and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Rapport Therapeutics' score of -0.14 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

CorMedix beats Rapport Therapeutics on 11 of the 16 factors compared between the two stocks.

How does CorMedix compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and CorMedix (NASDAQ:CRMD) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 3.5% of CorMedix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, HUTCHMED had 1 more articles in the media than CorMedix. MarketBeat recorded 3 mentions for HUTCHMED and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat HUTCHMED's score of 1.05 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CorMedix has a net margin of 45.25% compared to HUTCHMED's net margin of 0.00%. CorMedix's return on equity of 45.57% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
CorMedix	45.25%	45.57%	24.76%

HUTCHMED has higher revenue and earnings than CorMedix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$549.12M	3.97	$456.91M	N/A	N/A
CorMedix	$311.71M	1.87	$163.05M	$2.13	3.49

HUTCHMED has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

HUTCHMED currently has a consensus price target of $14.87, suggesting a potential upside of 18.84%. CorMedix has a consensus price target of $14.86, suggesting a potential upside of 99.69%. Given CorMedix's stronger consensus rating and higher possible upside, analysts plainly believe CorMedix is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

CorMedix beats HUTCHMED on 9 of the 15 factors compared between the two stocks.

How does CorMedix compare to GH Research?

CorMedix (NASDAQ:CRMD) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

CorMedix has a net margin of 45.25% compared to GH Research's net margin of 0.00%. CorMedix's return on equity of 45.57% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
GH Research	N/A	-21.81%	-21.10%

CorMedix presently has a consensus target price of $14.86, indicating a potential upside of 99.69%. GH Research has a consensus target price of $42.78, indicating a potential upside of 41.32%. Given CorMedix's stronger consensus rating and higher possible upside, research analysts clearly believe CorMedix is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
GH Research	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67

34.2% of CorMedix shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Comparatively, 41.6% of GH Research shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CorMedix has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, GH Research has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

CorMedix has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.87	$163.05M	$2.13	3.49
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

In the previous week, GH Research had 9 more articles in the media than CorMedix. MarketBeat recorded 11 mentions for GH Research and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat GH Research's score of 0.70 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
GH Research	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CorMedix beats GH Research on 11 of the 15 factors compared between the two stocks.

Get CorMedix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRMD vs. The Competition

Export

Metric	CorMedix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$589.17M	$11.74B	$6.94B	$12.87B
Dividend Yield	N/A	2.71%	2.59%	9.91%
P/E Ratio	3.49	793.41	270.28	25.20
Price / Sales	1.87	771.35	597.84	98.50
Price / Cash	3.67	73.00	71.46	49.72
Price / Book	1.45	10.75	13.25	6.21
Net Income	$163.05M	$2.77B	$3.45B	$342.45M
7 Day Performance	-1.20%	3.28%	4.65%	4.41%
1 Month Performance	-15.74%	-1.35%	-0.79%	-0.28%
1 Year Performance	-27.98%	191.23%	77.75%	22.60%

CorMedix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRMD CorMedix	2.5401 of 5 stars	$7.44 -0.9%	$14.86 +99.7%	-31.2%	$589.17M	$311.71M	3.49	30	News Coverage Positive News Upcoming Earnings
MLYS Mineralys Therapeutics	3.5613 of 5 stars	$25.78 +1.0%	$49.33 +91.4%	+112.5%	$2.11B	N/A	N/A	28	Upcoming Earnings
HRMY Harmony Biosciences	4.3411 of 5 stars	$35.60 +1.0%	$42.63 +19.7%	+12.3%	$2.04B	$868.45M	14.21	200	News Coverage Earnings Report Analyst Forecast
RAPP Rapport Therapeutics	2.574 of 5 stars	$40.79 -0.5%	$57.86 +41.8%	+195.2%	$1.96B	N/A	N/A	N/A	Trending News Earnings Report Analyst Forecast Analyst Revision
HCM HUTCHMED	2.2667 of 5 stars	$11.55 +3.8%	$14.87 +28.7%	-23.3%	$1.94B	$548.51M	N/A	1,796	News Coverage Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRMD) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CorMedix (CRMD) Competitors

CRMD vs. MLYS, HRMY, RAPP, HCM, and GHRS

How does CorMedix compare to Mineralys Therapeutics?

Summary

How does CorMedix compare to Harmony Biosciences?

Summary

How does CorMedix compare to Rapport Therapeutics?

Summary

How does CorMedix compare to HUTCHMED?

Summary

How does CorMedix compare to GH Research?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CorMedix (CRMD) Competitors

CRMD vs. MLYS, HRMY, RAPP, HCM, and GHRS

How does CorMedix compare to Mineralys Therapeutics?

Is CRMD or MLYS more profitable?

Do analysts recommend CRMD or MLYS?

Which has better earnings and valuation, CRMD or MLYS?

Do institutionals and insiders have more ownership in CRMD or MLYS?

Which has more risk & volatility, CRMD or MLYS?

Does the media prefer CRMD or MLYS?

Summary

How does CorMedix compare to Harmony Biosciences?

Do analysts recommend HRMY or CRMD?

Does the media prefer HRMY or CRMD?

Which has more volatility & risk, HRMY or CRMD?

Is HRMY or CRMD more profitable?

Which has higher valuation and earnings, HRMY or CRMD?

Do institutionals & insiders have more ownership in HRMY or CRMD?

Summary

How does CorMedix compare to Rapport Therapeutics?

Is RAPP or CRMD more profitable?

Which has more risk & volatility, RAPP or CRMD?

Which has stronger valuation and earnings, RAPP or CRMD?

Do analysts prefer RAPP or CRMD?

Do insiders & institutionals hold more shares of RAPP or CRMD?

Does the media favor RAPP or CRMD?

Summary

How does CorMedix compare to HUTCHMED?

Do insiders & institutionals hold more shares of HCM or CRMD?

Does the media favor HCM or CRMD?

Is HCM or CRMD more profitable?

Which has better valuation and earnings, HCM or CRMD?

Which has more volatility & risk, HCM or CRMD?

Do analysts recommend HCM or CRMD?

Summary

How does CorMedix compare to GH Research?

Is CRMD or GHRS more profitable?

Do analysts rate CRMD or GHRS?

Do insiders and institutionals have more ownership in CRMD or GHRS?

Which has more volatility & risk, CRMD or GHRS?

Which has stronger valuation & earnings, CRMD or GHRS?

Does the media refer more to CRMD or GHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools